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In order to elucidate the biological variance between normal ovarian surface epithelial (NOSE) and epithelial ovarian cancer (EOC)
cells, and to build a molecular classifier to discover new markers distinguishing these cells, we analysed gene expression patterns of 65
primary cultures of these tissues by oligonucleotide microarray. Unsupervised clustering highlights three subgroups of tumours: low
malignant potential tumours, invasive solid tumours and tumour cells derived from ascites. We selected 18 genes with expression
profiles that enable the distinction of NOSE from these three groups of EOC with 92% accuracy. Validation using an independent
published data set derived from tissues or primary cultures confirmed a high accuracy (87–96%). The distinctive expression pattern
of a subset of genes was validated by quantitative reverse transcription–PCR. An ovarian-specific tissue array representing tissues
from NOSE and EOC samples of various subtypes and grades was used to further assess the protein expression patterns of two
differentially expressed genes (Msln and BMP-2) by immunohistochemistry. This study highlights the relevance of using primary
cultures of epithelial ovarian cells as a model system for gene profiling studies and demonstrates that the statistical analysis of gene
expression profiling is a useful approach for selecting novel molecular tumour markers.
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Epithelial ovarian cancer (EOC), a complex disease, is the second
most common gynaecological cancer, and accounts for nearly half
of the deaths associated with gynaecological pelvic malignancies.
Largely asymptomatic, over 70% of patients with ovarian cancer
are already at an advanced stage of the disease at initial diagnosis.
Considering the morphological, anatomical and clinical differences
between tumours, three main classification parameters have
emerged, which are based on histological subtype (serous,
endometrioid, clear cells, mucinous, Brenner), disease stage
(I–IV) and tumour grade (0–3). However, early detection of
ovarian cancer is rare, and screening program in the general
population have been unsuccessful. Recent studies have focused on
gene expression patterns observed for multiple tumours to identify
the molecular events involved in the development of cancer in
order to uncover diagnostic and prognostic markers as well as
new therapeutic targets. Promising results have been reported
in several cancers, including bladder, colon and breast cancers
(Neibergs et al, 2002; van’t Veer et al, 2002; Dyrskjot et al, 2003), of
gene expression profiling as a new means for identifying diagnostic
and prognostic targets. While this approach has been applied to
ovarian cancer (Adib et al, 2004; Donninger et al, 2004; Hibbs et al,
2004; Lancaster et al, 2004; Lee et al, 2004; Lu et al, 2004; Santin
et al, 2004; Warrenfeltz et al, 2004; Zhang et al, 2005), resulting in
the identification of several hundred genes differentially expressed
between NOSE (normal ovarian surface epithelia) and EOC, less
than 10% of these genes were identified in common by at least two
reports (Le Page et al, 2004). Although sample size, methods of
evaluation and expression platforms vary and could account for
differences in gene expression profiles, additional independent
studies are required for cross-comparison to identify reliable gene
markers that vary in expression.
Gene profiling by microarray studies can also be applied to
tumour classification, identification of tumour subtypes, or used to
predict disease outcome. Expression-based classification schemes
have been applied to distinguish ovarian cancers from other
tumour types (Golub et al, 1999; Ross et al, 2000; Ramaswamy
et al, 2001), but rarely to distinguish normal samples from ovarian
cancers. A recent study classified pooled normal epithelial samples
from ovarian tumours based on the gene expression of CLDN3
and VEGF (Lu et al, 2004). The choice of model system to study
molecular profiling is a critical factor that may account for
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svariations in gene expression patterns. As normal epithelial cells
are generally quiescent, differential gene expression observed
between tissues of NOSE and EOC may reflect differences not
necessarily related to oncogenic transformation. In ovarian cancer,
primary cultures derived from NOSE and tumour tissue have been
described (Lounis et al, 1994). In the case of EOC tissues, primary
cultures have the advantage of being relatively free of non-
transformed cell population. NOSE cultures, derived by scraping
the surface of the ovary, are highly homogenous and provide
conditions in which normal cells replicate over a limited number
of generations. In addition, a recent study comparing candidate
genes able to stratify low- from high-malignancy tumours
(identified in primary cultures and tumour tissues) showed that
candidate genes identified in primary cultures were also able to
reclassify samples derived from tumour tissues (Ouellet et al,
2005). Based on these advantages, we studied primary cultures
enriched over several passages. Using 65 independent samples, we
identified gene expression patterns by Affymetrix oligonucleotide
microarray analyses, which enabled the stratification of NOSE
from EOC and was further supported by tissue array analyses.
MATERIALS AND METHODS
Patients, cell culture and clinical material
Tissue samples and sera were obtained with informed consent
from participants. Tumour samples were collected from surgeries
performed at the Centre Hospitalier de l’Universite ´ de Montre ´al
(CHUM). Histopathology, grade and stage of tumours were
assigned according to the International Federation of Gynecology
and Obstetrics (FIGO) criteria. Normal tissues were obtained from
tumour-free participants that have undergone oopherectomies.
Primary cell cultures from NOSE and EOC samples were
established as described (Kruk et al, 1990; Lounis et al, 1994)
and used for microarray analysis. Cells in primary culture were
maintained in OSE media consisting of 50:50 medium 199:105
(Sigma, St Louise, MO, USA) supplemented with 10% fetal bovine
serum, 2.5mgml
 1 amphotericin B and 50mgml
 1 gentamicin
(Kruk et al, 1990). The samples used for microarray, reverse
transcription (RT)–PCR and tissue array immunohistochemistry
(IHC) studies are presented in Table 1.
RNA preparation and microarray
Total RNA was extracted with TRIzolt reagent (Gibco/BRL, Life
Technologies Inc., Grand Island, NY, USA). RNA was extracted
directly from cells grown to 80% confluency. RNA quality was
monitored by agarose gel electrophoresis, and independently by
the 2100 bioanalyzer using the RNA 6000 Nano LabChip kit
(Agilent Technologies, Germany). Biotinylated hybridisation target
was prepared from total RNA as described (Tamayo et al, 1999).
Affymetrix HuFL arrays were used to hybridise label targets, and
gene expression levels were calculated for each EST from the
scanned image by the Affymetrix GeneChip MAS4 software. This
gene chip contains 6800 probe sets representing known genes and
ESTs (Affymetrix.com). Microarray experiments were performed
at the McGill University and Genome Que ´bec Innovation Centre.
The detailed protocol is available at www.genomequebec.mcgill.ca/
center.php. The raw data of each experiment, including data used
for training and test sets, were normalised according to the mean
of the global intensity expression values adjusted to 100 units.
After normalisation, we considered all values below 20 as technical
noise and rescaled these values to 20. Next, we removed for further
analysis all expression values for a given probe set with a poor
reliability score or ‘A’ call (ambiguous signal) that occurred across
all samples. Using this filtering approach, the expression values of
Table 1 Specimen and clinical data of ovarian cancer patients used in each experiments
Grade Stage
Experiments Samples LMP 1 2 3 Unknown Low (1–2) High (3–4) Solid tumours Ascites
Training set (n¼65) Normal n¼11
Serous n¼40 6 1 8 25 4 36 23 17
Endometrioid n¼93 6 3 6 5 5
Clear cell n¼22 1 1 0 2
Mixed n¼11 1 1 0
Mucinous¼11 1
Undifferentiated n¼13 0 1
Total tumours n¼54 7 1 11 37 1 10 44 29 25
Test set primary culture (n¼23) Normal and benign n¼6
Serous n¼11 3 3 5 3 7 1 9
Endometrioid n¼11 1 1 0
Clear cell n¼11 1 0 1
Mixed n¼33 3 1 2
Undifferentiated n¼11 1 1 0
Total tumours n¼17 3 3 11 3 13 4 12
Test set tissue (n¼137)
a Normal and benign n¼5N S N S 5 0
Serous n¼81 6 3 21 41 10 NS NS 81 0
Endometrioid n¼33 10 10 13 NS NS 33 0
Clear cell n¼8 8 NS NS 8 0
Mucinous n¼10 7 3 NS NS 10 0
Total tumours n¼132 6 20 34 62 10 NS NS 137 0
Tissue array (n¼89) Normal n¼20
Serous n¼21 4 5 5 7 1 8 13 21 0
Endometrioid n¼27 13 7 5 2 17 10 27 0
Clear cell n¼17 5 9 3 11 6 17 0
Mixed n¼43 1 2 2 4 0
Total tumours n¼69 4 18 17 24 6 38 31 69 0
LMP¼low malignant potential.
aFrom publicly available data sets (Welsh et al, 2001; Schwartz et al, 2002; Ouellet et al, 2005). ns: nonspecified.
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Values were then converted into log10 for further analysis. Both the
raw and normalised data sets are available at http://www.genome-
quebec.mcgill.ca/ovarian/.
Clustering
We carried out hierarchical clustering analysis using GeneSpringt
software (Silicone Genetics) on the filtered data set. We used the
distance branch of 0.1 with a Pearson correlation as a similarity
metric.
Supervised class comparison
Three statistical tests were used to identify classifiers. The signal-
to-noise metric Sx¼(m1 m2)/(s1þs2) was applied, where m
represents the mean and s the standard deviation of either class
1 or 2 (Golub et al, 1999). Here, class 1 represents NOSE samples
and class 2 represents tumour samples. Only genes with |Sx|X0.05
were selected. Classifiers were also identified using the significance
analysis of microarray (SAM) software described (Tusher et al,
2001) and available at http://www-stat-class.standford.edu/SAM/
SAMServlet. One thousand permutations were applied in an
unpaired filtered data set. The threshold was chosen according to a
determined false discovery rate (FRDo5%). A non-parametric test
was also performed using the Mann–Whitney U-test included in
the GeneSpringt software, including an FDR correction (P-value
o0.05 or Po0.15) (Silicone Genetics).
Tumour classification and prediction
To classify samples, we used a k-nearest neighbour algorithm
included in the GeneSpringt software (Silicon Genetics). Leave-
one-out cross-validation approach was used to evaluate the
predictors in the training set. A class prediction test was used to
predict the independent test samples based on classifiers defined
from the training set. Each sample from the test set is classified by
finding the k-nearest neighbouring training samples. The neigh-
bour number was n 1, where n is the smallest number of samples
in one group. The decision cutoff was Po0.2. All sample sets
(training and test sets) were evaluated with the same algorithm.
Quantitative PCR
As previously described (Ouellet et al, 2005), RNA was linearly
amplified by Alethia Biotherapeutics (Montreal, QC, Canada). The
RAMP RNA produced is (þ) sense. The cDNA synthesis was
performed according to the protocol of the SuperScriptt First-
Strand Synthesis System for RT–PCR (Invitrogen Life Technolo-
gies) with a starting amount of 2mg of RNA; the RT was performed
with random hexamers. The condition of the PCR reaction
(temperature, specificity) was defined by conventional PCR.
Positive and negative controls were introduced in all experiments.
Quantitative PCR (Q-PCR) was performed using Rotor-gene 3000
Real-Time Centrifugal DNA Amplification System (Corbet Tumor
Tissues Research, NSW, Australia). We used the Quantitectt SYBR
Green PCR (Qiagen Inc., ON, Canada) reaction mixture according
to the manufacturer’s instructions. Serial dilutions were performed
to generate a standard curve for each gene tested in order to define
the efficiency of the Q-PCR reaction, and a melt curve was
constructed to confirm the specificity of the reaction. Experiments
were performed in duplicate. Control RNA (Erk) was chosen based
on stable expression in 69 ovarian samples containing normal and
tumour types as previously described (Ouellet et al, 2005). Primers
are described in Supplementary Table 2. We used the Pfaffl
analysis method to measure the relative quantity of gene
expression (Pfaffl, 2001). Statistical analyses were performed using
the Student’s t-test.
Tissue array and IHC
The following monoclonal antibodies were used in IHC: anti-
ATPaseb1, anti-BMP-2, anti-TNFR1 (Santa-Cruz Biotechnology,
CA, USA) and anti-mesothelin (Msln) (Biogenex, San Roman, CA,
USA). A tissue array containing 94 cores of ovarian epithelial
tissues (Table 1) was amassed and used for IHC studies. Briefly, the
tissue array was heated at 601C for 30min, de-paraffinised in
toluene and rehydrated in a gradient of ethanol. To unmask
antigen, the slides were submerged in 901C citrate buffer (0.01 M
citric acidþ500ml Tween 20l
 1 adjusted to pH 6.0) (JT Baker,
Philipsburg, NJ, USA) for 15min. The tissue was blocked with
a protein-blocking serum-free reagent (DakoCytomation Inc.,
Mississauga, ON, Canada) and incubated with different antibodies
overnight at 41C in a humid chamber. The optimal concentration
for each primary antibody was determined by serial dilutions.
Subsequently, endogenous peroxidase activity was quenched
by treatment with 3% H2O2. The array was then incubated
with a secondary biotinylated antibody (DakoCytomation Inc.,
Mississauga, ON, Canada) for 10min, followed by incubation with
a streptavidin–peroxidase complex (Dako Diagnostics Canada
Inc., Mississauga, ON, Canada) for 10min at room temperature.
Reaction products were developed using diaminobenzidine (brown
stain) containing 0.3% H2O2 as a substrate for peroxidase, and
nuclei were counterstained with diluted haematoxylin (blue stain).
Epithelial zones were scored according to the intensity of staining
(0 for absence, 1 for very weak, 2 for weak, 3 for moderate and
4 for high intensity). Each array was independently analysed in a
blinded study by two independent observers. Statistical analyses
were performed using the Mann–Whitney U-test.
RESULTS
Comparative gene profiling of normal epithelial cells
(NOSE) and epithelial ovarian tumours (EOC)
To identify markers that may be associated with the progression
towards a malignant phenotype, we used oligo-microarrays to
analyse gene expression profiles of normal or tumoral primary
cultures of ovarian epithelial cells. Primary cultures were derived
from specimens selected on the basis of the disease course before
treatment of the patient (e.g. no chemotherapy). Primary cultures
from 54 malignant tumours and 11 NOSE samples were analysed
by microarray. The samples represent as much as possible the
diversity of EOC in terms of grade and histopathology (Table 1);
Brenner tumours were not represented in our set.
To gain insight into genes whose expression is associated with
ovarian malignant transformation, we analysed the expression
array data derived from HuGeneFL 6800 Affymetrix GeneChip
s
using three different supervised classification methods. The group
of NOSE samples was compared to the 54 EOC samples. A total of
505 genes were selected by at least one algorithm (data not shown),
where 126 ESTs were identified in common by all three algorithms
that represent genes that were significantly differentially expressed
when NOSE samples were compared with EOC samples (Figure 1
and Supplementary Table 1). About 25% of these genes have
previously been shown to be differentially expressed in ovarian
cancer cells relative to normal ovarian cells (partially shown in
Table 2) (Le Page et al, 2004). The 126 genes are associated with
known biological functions such as angiogenesis, growth and
proliferation, signalling, cell adhesion and metastases, and are
potential oncogenes and tumour suppressors (Table 2). The
expression profile of these 126 genes, subjected to a two-way
hierarchical cluster analysis (Figure 1), identified several char-
acteristic profiles that differed among the groups analysed. The
NOSE samples clustered together with the low malignant potential
(LMP) tumours and three grade 2 tumours, forming a group
considered as low-grade samples. The majority of tumours are
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type. We also noticed that ascites show a more homogenous
profile in comparison to the solid invasive tumours and, clustered
in a sub-branch. The unsupervised clustering analysis showed
that these 126 genes were not able to discriminate NOSE samples
from LMP samples in contrast to invasive EOC samples. This
suggests that LMP tumours should be analysed separately from
the invasive tumours to identify specific gene markers for low-
grade disease.
Selection of genes distinguishing subclasses of ovarian
tumours
Based on the results of our initial analysis, we subsequently used a
supervised approach to select genes that were able to differentiate
the major groups of tumours (LMP, ascites and solid invasive
tumours) that clustered in the unsupervised analysis. For this
purpose, the three groups of tumours were individually compared
to the NOSE samples. Ten genes were differentially expressed in
LMP tumour cells (Figure 2A), 16 genes were differentiated in solid
invasive tumours (Figure 2B) and 270 genes were differentially
expressed in ascites tumours (Figure 2C). Among these 270 genes
were the 16 differentially expressed genes identified in the solid
invasive tumour group of invasive tumours.
As there are no common genes found in the independent
analyses of LMP, ascites and invasive tumour groups that
distinguished them from NOSE samples, we tested as a classified
model the 10 genes differentially expressed in LMP combined with
the 16 differentially expressed genes found in common in the
analyses of ascites and invasive solid tumours. As an objective
prediction of low- and high-malignant ovarian tumours using a
limited set of genes could be appropriate for clinical use, we
selected gene classifiers showing at least a 1.5-fold gene expression
difference between NOSE samples and tumour samples. Using this
approach, we reduced the original set of 26 markers to a subset of
18 markers that were the most predictive (Table 3). Each of the 65
tumours was reclassified according to the expression pattern of the
18 gene classifiers. This classifier predicted correctly 60 out of 65
samples (92%) (Table 4). All normal and ascites samples were
correctly classified, and only three solid tumours (1.5%) were
incorrectly classified as NOSE. This classifier showed greater
accuracy in comparison to the large set of 126 genes selected in
Figure 1B (Table 4). The incorrectly classified samples included
one grade B (LMP) and one grade 2 serous tumours as well as one
unknown grade tumour. Interestingly, this classifier allowed a
lower ratio of errors/correctly classified (r¼0.05) than the set of
126 genes. To validate the classifier, an additional independent test
set of 23 primary culture samples and 137 arrays of surgical
specimens from publicly available data sets derived from
Affymetrix HuFL GeneChip platform (Welsh et al, 2001; Schwartz
et al, 2002; Ouellet et al, 2005) were tested. The set of 23 primary
culture samples contained two LMP serous ascites. All these
samples were normalised the same way as our training set. The
algorithm used for class prediction was the same as previously
used (k-nearest neighbour). Instead of a cross-validation scheme,
these new samples were predicted using a class prediction scheme.
The tumour potential was predicted, and resulted in 87% accuracy
for the primary culture sample set and 96% accuracy for the tissue
sample set (Table 4).
Validation by Q-PCR
To validate the differential expression observed by DNA micro-
array, we tested the expression of 13 markers encoding known
proteins by real-time Q-PCR. This set of 13 markers was composed
of a subset of 10 markers selected from the classifier analysis
(MSLN, RP-1, ITPR3, HoxB7, ATPaseb1, ST-5, HoxB9, SmLIM,
A2LP and HSU79271) in addition to three genes (TNFRI, KRT7
and BMP-2) that not only differentiate NOSEs and EOCs but also
reveal differences between ascites and solid tumours (Figure 1 and
Supplementary data 1). RNA from primary cultures of nine NOSE,
eight malignant EOC or six LMP tumours already used for the
profiling analysis was randomly chosen as templates for these
assays. As shown in Figure 3, in general, Q- PCR results were
consistent with expression microarray data patterns. A significant
difference (Po0.05) was noticed between the expression levels of
NOSE and EOC for each of the tested genes, with the exception of
RP-1 and SmLIM (Figure 3A and B, respectively).
We chose the 11 genes that were validated by Q-PCR as
differentially expressed between NOSE and EOC, and tested
whether their relative RNA expression monitored by Q-PCR could
classify the samples using the ‘leave-one-out’ cross-validation
scheme. All tumours were correctly classified; however, two NOSE
samples were indistinguishable from LMP, giving a total of 87%
accuracy. Even with a small set of samples, these results showed
that PCR classification using a smaller set of marker genes could
reach the accuracy rate obtained by microarray data.
Immunochemical expression of ATPaseb1, TNFR1, BMP-2
and Msln in ovarian tumours
We also determined whether the protein encoded by the classifier
genes had similar classifying potential. For this purpose, we used
immunohistochemical assays on a tissue array containing 20 NOSE
ADORA2b
BST-2
ST-5
PLB
Sm-LIM
PrP
KRT7
TNFRI
BMP-2
MSLN
ITPR3
ATPase 1  
Ηox-B7
NOSE17
NOSE112
LMP60
LMP75
NOSE69
EOC73
EOC79
EOC109
NOSE113
EOC46
LMP58
NOSE18
LMP59
LMP64
EOC115
NOSE39
LMP65
EOC88
EOC173
NOSE428
NOSE40
NOSE54
NOSE461
NOSE427
EOC224
EOC20
EOC86
EOC87
EOC90
EOC97
EOC94
EOC41
EOC42
EOC43
EOC271
EOC328
EOC331
EOC71
EOC80
EOC237
EOC108
EOC227
EOC231
EOC232
EOC899
EOC235
EOC1012
EOC56
EOC63
EOC91
EOC93
EOC962
EOC70
EOC197
EOC242
EOC230
EOC51
EOC236
EOC190
EOC229
EOC62
EOC47
EOC84
EOC89
E
x
p
r
e
s
s
i
o
n
 
s
c
a
l
e
3
1.3
2
NOV
EOC
Ascites
LMP
Figure 1 Hierarchical clustering of gene analysis expression of 11 normal
ovarian epithelia (NOSE) and 55 epithelial ovarian tumours (EOC) from
primary culture. Sample clusters based on 126 genes differentially
expressed in tumour samples vs normal epithelia. Clustering was carried
out based on the genes retrieved by class comparison (P-value o0.05,
FDRo0.05, |Sx|40.50). Genes were selected by three statistic algorithms
(see Materials and Methods). Each row represents a gene and each column
represents a sample. Identity of each sample in the clusters is shown on the
left of the figure. Colour intensity represents level of gene expression
transformed in log10. LMP¼low malignant potential tumours; Msln refers
to the protein; MSLN refers to the gene.
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sTable 2 Biological function of genes deregulated in EOC
Gene ID Unigene_ID Title Gene
Regulation in
EOC P
a
Reported in
other studies in
relation to
ovarian cancer
Cell cycle/growth K01911_at Hs.1832 Neuropeptide Y NPY Up 0.0035 No
D21878_at Hs.169998 Bone marrow stromal cell antigen 1 BST1 Up 2E 05 No
U72066_at Hs.29287 Retinoblastoma-binding protein 8 RBBP8 Up 2E 05 No
Oncogenes or tumour
suppressors
X77548_at Hs.99908 Nuclear receptor coactivator 4 NCOA4 Up 0.0005 No
J04102_at Hs.85146 v-ets avian erythroblastosis virus E26
oncogene homolog 2
ETS2 Up 0.001 Ni
L20861_at Hs.152213 Wingless-type MMTV integration site
family, member 5A
WNT5A Up 3E 05 Yes
X16662 Hs.87268 Annexin A8 ANXA8 Up 5E 06 No
U61262_at Hs.90408 Neogenin (chicken) homolog 1, netrin
receptor
NEO1 Up 2E 06 Yes
U15131_at Hs.79265 Suppression of tumorigenicity 5 ST5 Down 2E 05 No
Angiogenesis M34539 Hs.752 FK506-binding protein 1A (12kD) FKBP1A/FKPB12 Up 7E 05 No
M30257 Hs.109225 Vascular cell adhesion molecule 1 VCAM1 Up 5E 05 Yes
D49950_at Hs.83077 Interleukin 18 (interferon-gamma-inducing
factor)
IL18 Up 2E 05 Yes
M31551_s_at M31551 All_M31551 576-1134, Human urokinase
inhibitor (PAI-2) gene
PAI-2 Up 0.0002 Yes
J04513_at J04513 Human basic fibroblast growth factor
(bFGF/FGF2)
bFGF Up 0.0002 Yes
X72012_at Hs.76753 Endoglin (Osler–Rendu–Weber
syndrome 1)
ENG Down 0.0002 Yes
M22960_at Hs.73853 Bone morphogenetic protein 2 BMP-2 Up Yes
Adhesion D13666 Osteoblast specific factor 2 (fasciclin I-like) OSF-2 Up 0.0002 Yes
D84424 Hs.57697 Hyaluronan synthase 1 HAS1 Up 0.0006 No
M28882 Hs.211579 Melanoma adhesion molecule MCAM Down 2.7E 6N o
M29277 Hs.211579 Melanoma adhesion molecule MCAM Down 8.54E 6N o }
M59911 Hs.265829 Integrin, alpha 3 (antigen CD49C, alpha 3
subunit of VLA-3 receptor)
ITGA3 Up 5E 06 No
U41767 Hs.92208 A disintegrin and metalloproteinase domain
15 (metargidin)
ADAM15 Up 0.0042 Yes
Y00097_s_at Hs.118796 Annexin A6 ANXA6 Down 1E 05 No
Z26653 Hs.75279 Laminin, alpha 2 (merosin, congenital
muscular dystrophy)
LAMA2 Down 4E 05 Yes
D49950 Hs.83077 Interleukin 18 (interferon-gamma-inducing
factor)
IL18 Up 2E 05 Yes
M30257_s_at Hs.109225 Vascular cell adhesion molecule 1 VCAM1 Up 5E 05 Yes
U40282_at Hs.6196 Integrin-linked kinase ILK Down 1E 05 Yes
Metastasis D21337_at Hs.408 Collagen, type IV, alpha 6 COL4A6 Up 0.001 Yes
M90657_at Hs.3337 Transmembrane 4 superfamily member 1 TM4SF1 Up 0.0009 No
M22489_at Hs.73853 Bone morphogenetic protein 2 BMP2 Up 0.0006 Yes
L20861 Hs.152213 Wingless-type MMTV integration site
family, member 5A
WNT5A Up 3E 05 Yes
Transduction signal/
transcription factor
D25538 Hs.172199 Adenylate cyclase 7 ADCY7 Down 2E 05 No
L07597 Hs.149957 Ribosomal protein S6 kinase, 90kD,
polypeptide 1
RPS6KA1 Up 3E 05 No
M64497 Hs.288869 Nuclear receptor subfamily 2, group F,
member 2
NR2F2 Down 0.0004 No
U24576 Hs.3844 LIM domain only 4 LMO4 Up 1E 06 No
U28833 Hs.86724 Down syndrome critical region gene 1 DSCR1 Up 3E 06 No
X68487 Hs.45743 Adenosine A2b receptor ADORA2B Down 1E 06 No
J03161 Hs.155321 Serum response factor (c-fos serum
response transcription factor)
SRF Down 0.001 No
M62402 Hs.274313 Insulin-like growth factor binding protein 6 IGFBP6 Down 2E 05 Yes
M62403 Hs.1516 Insulin-like growth factor-binding protein 4 IGFBP4 Up 0.0004 Yes
L20861 Hs.120 Wingless-type MMTV integration site
family, member 5A
WNT5A Up 3E 05 Yes
M34539 Hs.752 FK506-binding protein 1A (12kD) FKBP1A/FKPB12 Up 7E 05 No
EOC¼epithelial ovarian cancer.
aMann–Whitney test.
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sand 69 EOC cores (Table 1). This assay was restricted by the
commercial availability of antibodies and thus we were not able to
test any of the seven of the 10 LMP classifying genes. Among the 11
classifiers of highly malignant tumours, we were able to test
ATPaseb1 and Msln expression. We also immunostained the tissue
array with keratin 19 as a positive control to visualise epithelial
cells. ATPaseb1 was expressed at a high level in both NOSE and
EOC (Figure 4). Although IHC detected apparently high levels of
expression of ATPase in both tissues, it was unable to discriminate
the samples based on the intensity of staining. In contrast to
ATPaseb1, Msln protein was weakly expressed in some normal
epithelial cells (Table 5) and more strongly in cancerous cells
(Figure 4). As already described (Chang et al, 2003; Ordonez, 2003;
Drapkin et al, 2004), Msln staining was observed on the apical
layer of tumour tissues (Figure 4). The intensity of staining was
correlated with the highest-grade tumours, where a significant
difference was observed between normal epithelia and grade 2 or
grade 3 tumours (Po0.03; Table 5). However, all serous tumours
stained for Msln regardless of the malignancy (Table 5), support-
ing the idea that Msln is a marker of serous tumours independently
of the grade and stage.
We also tested the expression of TNFR1 and BMP-2, two
upregulated genes in tumour ascites cells relative to NOSE samples.
As observed with ATPaseb1, TNFR1 was expressed at a high level in
both NOSE and EOC samples (Figure 4) and was unable to
discriminate the samples based on the intensity of staining. In
contrast, when expressed in NOSE tissues, the expression of BMP-2
was globally weaker than in tumour tissues (Table 5 and Figure 4).
In contrast to Msln expression, no correlation between tumour
grade and BMP-2 expression was observed, and the clear cell
tumours showed a stronger staining than endometrioid and serous
tissues. We also estimated the performance of BMP-2 as an
individual marker of ovarian cancer. Threshold of moderate
staining (3þ) yielded the best possible sensitivity and specificity
values to predict the tumoral status potential.
DISCUSSION
Owing to the complexity of ovarian cancer and, in particular, the
presence of mixed subtypes, there is considerable interest in
defining a molecular signature for ovarian cancer. Using micro-
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Figure 2 (A) Hierarchical clustering of gene analysis expression of 11 normal ovarian epithelia and six EOC of low malignant potential. Sample clusters
and gene profile based on 11 genes differentially expressed in LMP samples. Genes were identified using U algorithm (Po0.15). (B) Hierarchical clustering
of gene analysis expression of 11 ovarian epithelia and 24 solid invasive ovarian tumours. Supervised sample clusters and gene profile based on 16 genes
differentially expressed in malignant tumour samples are shown. Genes were identified using U algorithm (Po0.05). (C) Hierarchical clustering of gene
analysis expression of 11 ovarian epithelia and 23 ovarian samples from malignant ascites. Supervised sample clusters and gene profile based on 270 genes
differentially expressed ascites are shown. Genes were identified using U algorithm (Po0.05). Each row represents a gene and each column represents a
sample. Colour intensity represents level of gene expression transformed in log10 corresponding to the expression scale shown on the left side of the
figure. NOSE¼normal ovarian epithelia; EOC¼epithelial ovarian cancer. Colour bar at the bottom of the gene expression matrice shows the class of
sample.
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sarray analysis, we were able to identify distinctive profiles of gene
expression of ovarian cancer cells. These profiles distinguished
LMP tumours, malignant tumours and malignant cells from
ovarian ascites. These three groups of ovarian cancer cells are
currently distinguishable by their invasive potential but not by
histopathologic subtypes as previously observed (Schaner et al,
2003). Low malignant potential tumours are the least aggressive
tumours of the studied groups and rarely invade the peritoneal
cavity or migrate to the omentum. In contrast to solid malignant
tumours that invade the stroma of the ovary and may be associated
with local sites of progression, ascites tumour cells may implant at
distal sites in the peritoneal cavity. The ability, in our study, to
distinguish solid tumours vs ascites based on gene expression
signatures may reflect different biological characteristics of these
cells associated with the invasiveness and migration potential, as
highlighted by the number of genes associated with angiogenesis,
adhesion and metastasis processes (Table 2).
We also evaluated the classification ability of the expression of
several genes detected by microarray. The predictive property
of the gene set classifier may have considerable clinical importance
if validated in a large set of tissue samples. Indeed, we were able
to correctly classify approximately 90% of the samples. This
represents a result comparable to what has been obtained with
other types of cancer (Golub et al, 1999; Beer et al, 2002; Shipp et al,
2002; van’t Veer et al, 2002; Dyrskjot et al, 2003; Gordon et al, 2003;
Simon, 2003), and represents the first report of this type in ovarian
cancer. The success of our approach may in part be explained by
the choice of the model system, which does not rely on primary
undissected tumour tissue that may contain several cell types. In
particular, we have previously demonstrated that even short-term
passage of primary cultures results in an enriched homogeneous
cell population (Lounis et al, 1994). The absence of non-malignant
contaminating cells in our samples has probably allowed a strict
selection of genes specifically expressed in epithelial cells. The
second reason is the strategy of using the combination of small
sets of specific genes to build a classifier able to differentiate
simultaneously low- and high-grade malignant tumours. Gene-level
expressions observed by Q-PCR confirmed the usefulness of this
method and allowed for the distinction of tumour samples, which
not only validated the biological relevance of the gene markers but
also supported the use of Q-PCR as a new diagnostic/prognostic
tool for determining tumour class. Although tumour classification
based on gene expression detected by RT–PCR has already been
successfully applied in mesothelia cancer (Gordon et al, 2003), the
validity of this method for ovarian cancer has to be confirmed
prospectively in a larger set of patient specimens.
Table 3 Description of 18 genes forming the ovarian tumour classifier
Probe set
HUFL Unigene Name Symbol
Regulation in
ovarian tumours Ratio P
a
Classifier of
malignancy
X94232_at Hs.78335 Microtubule-associated protein 2, RP family RP1/MAPRE2 Down 0.6 2E 04 Invasive
X83416_s_at PrP gene, exon 2 PRP Up 2.1 1E 04 Invasive
X68487_at Hs.45743 A2b adenosine receptor. ADORA2B Down 0.46 2E 05 Invasive
U40434_at Hs.155981 Mesothelin or CAK1 antigen precursor
mRNA
MSLN Up 2.5 2E 04 Invasive
U16799_s_at Hs.78629 Na,K-ATPase beta-1 subunit mRNA ATPaseb1 Up 4.5 2E 05 Invasive
U15131_at Hs.79265 p126 (ST5) mRNA, complete cds. ST-5/HTS1 Down 0.6 2E 04 Invasive
U01062_at Hs.77515 type 3 inositol 1,4,5-trisphosphate receptor
(ITPR3)
ITPR3 Up 2.7 2E 04 Invasive
M63603_at Hs.85050 Phospholamban mRNA, complete cds. PLN Down 0.3 4E 05 Invasive
M16937_at Hs.819 Homeobox c1 protein; homeobox B7 HoxB7 Up 2.5 1E 05 Invasive
HG1612-
HT1612_at
MARCKS Down 0.4 5E 05 Invasive
D28137_at Hs.118110 BST-2 BST-2 Down 0.5 2E 04 Invasive
U79275_at Hs.27414 Human clone 23947 mRNA HSU79275 Up 2 0.149 LMP
U70671_at Hs.43509 A2RP; Human ataxin-2 related protein
mRNA, partial cds.
A2RP Down 0.5 0.149 LMP
U60269_cds3_at U606269 Up 1.5 0.149 LMP
U46006_s_at Hs.10526 Smooth muscle lim protein SmLIM Down 0.6 0.149 LMP
U07664_at HB9 homeobox gene, exons 2 and 3 and
complete cds.
HoxB9 Up 2.5 0.114 LMP
M18700_s_at Elastase III A gene, exon 8 ELIII Up 1.9 0.093 LMP
HG830-
HT830_at
HG830-
Ht830
Up 1.7 0.093 LMP
Gene classifier list of 18 genes discriminating low malignant potential (LMP) tumours and invasive tumours from normal ovarian surface epithelial samples.
aMann–Whitney test.
Table 4 Molecular classification of ovarian tumours used in different sets of samples
Sample set Gene classifiers Correctly classified (n/%) Errors Nonclassified Ratio (error/correct)
Training set (n¼65) 4888 genes 33/51 8 24 0.24
130 genes 52/80 8 5 0.15
18 genes 60/92 3 2 0.05
130 genes 132/96 4 1 0.06
Test set tissue (n¼137) 18 genes 132/96 2 3 0.03
Test set (n¼23) 130 genes 18/78 2 3 0.11
18 genes 20/87 1 2 0.05
k-neighbour class prediction of different sample sets. Cutoff 0.2.
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sInterestingly, our LMP tumours showed the least distinct
profile in comparison to NOSE (Figure 1), which correlates with
the weak aggressive potential of these tumours and the favourable
prognostic for the patient. The present results correlate well with
recent attempts to distinguish LMP and solid malignant tumours
using a microarray and gene profiling approach (Gilks et al, 2005;
Meinhold-Heerlein et al, 2005; Ouellet et al, 2005). Here, we
detected only a very small set of genes differentially expressed
in LMP tumours. Those genes are genes encoding for unknown
proteins such as HSU79275, U60269, HG830-HT830, and genes
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Figure 3 Validation by real-time Q-PCR. A 2mg portion of RNA
extracted from primary culture was retro-transcribed and used for real-
time Q-PCR using specific primers for RP-1, MSLN, ATPaseb1, HoxB7, ST-
5, ITPR3, TNFR1, KRT7 and BMP-2 in eight malignant samples and nine
NOSE (normal ovarian surface epithelia) (A), A2RP, HSU79271, HoxB9
and SmLIM in six LMP (low malignant potential) samples and nine NOSE
(B). Each expression level was normalised to that of the control RNA.
Relative fold change expression is the ratio of the 61 NOSE gene
expression to that of other samples. Owing to the downregulated profile of
ST-5 gene expression, PCR was performed using EOC908 as reference.
Green colour represents expression ratio lower than 1, black represents
expression ratio equal to 1 and red represents expression ratio higher than 1.
NOSE LMP EOCs EOCcc EOCe
ATPase1 1
Msln
TNFRI
BMP-2
Figure 4 Immunohistochemistry of NOSE and EOC tissues. Expression of ATPaseb1, MSLN, TNFR1 and BMP-2 in normal ovarian surface epithelium
(NOSE), low-malignant (LMP) and high-malignant serous (EOCs), clear cell (EOCcc) and endometrioid (EOCe) ovarian cancer tissues. Keratin 19 is strongly
expressed in all three tissue types. ATPaseb1 and TNFRI are expressed in all tissue types. Mesothelin and BMP-2 are weakly expressed in NOSE tissues,
whereas they are more strongly expressed in EOC tissues. Note the apical expression of Msln.
Table 5 Immunohistochemical staining of an ovarian tissue array with
anti-mesothelin and anti-BMP-2 antibodies
P
a 0( n)1 + ( n)2 + ( n)3 + ( n) 4+(n)
Mesothelin Normal (n¼20) 76 610
(n¼4) 0.01 0 0 112
Grade 1 (n¼18) 0.25 8 2 630
Grade 2 (n¼17) 0.03 7 253
Grade 3 (n¼24) 0.01 7 3 21 0 2
Clear cells
(n¼17)
0.41 10 0 340
Endometrioid
(n¼27)
0.25 13 3 461
Serous (n¼21) o0.01 1 2 396
Mixed (n¼5) 0.14 1 1 111
Total tumours
(n¼70)
0.07 25 6 11 20 8
BMP-2 Normal (n¼20) 80 7 50
Grade LMP
serous (n¼4)
0.25 1 1 0 02
Grade 1 (n¼18) 0.20 8 0 1 45
Grade 2 (n¼17) o0.01 1 1 2 31 0
Grade 3 (n¼24) o0.01 3 1 4 41 2
Clear cells
(n¼17)
o0.01 1 0 1 01 6
Endometrioid
(n¼27)
0.04 8 1 3 51 0
Serous (n¼21) 0.06 5 2 3 56
Mixed (n¼5) 0.25 2 0 0 12
Total tumours
(n¼70)
0.05 16 3 7 11 34
Bold values highlight the positive cancerous samples and the negative normal epithelia
samples. LMP¼low malignant potential.
at-Test.
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sencoding for proteins without a clear function related to
oncogenesis, with the exception of the gene SAS (sarcoma amplified
sequence). Owing to its close localisation with MDM2, an inhibitor
of p53, the SAS oncogene is often associated with the amplification
of MDM2 in human sarcomas (Meltzer et al, 1991). In ovarian
cancer expression, MDM2 is more characteristic of serous LMP
(Palazzo et al, 2000). A deeper analysis would be necessary to
determine the potential involvement of SAS and MDM2 and their
prognostic value in serous LMP cancer. In addition, the small
number of genes detected as differentially expressed between LMP
and NOSE suggests that these tumours have a very similar profile to
NOSE cells, and also suggests that a better molecular distinction
between NOSE and LMP will need further investigation.
In the context of tumour suppressors involved in ovarian
cancer, much attention has focused on the role of BRCA and p53.
Whereas p53 mutation appears to be frequent (Marks et al, 1991;
Okamoto et al, 1991), BRCA mutation occurs in less than 10% in
all diagnosed cases (Ford et al, 1994; Cass et al, 2003) and
represents a small minority of ovarian cancers. Here, we identified
ST-5/HTS1 as a tumour suppressor gene downregulated in the
majority of ovarian primary cultures derived from malignant
tumours. ST-5 has been initially identified as a HeLa tumour
suppression gene (Lichy et al, 1992; Amid et al, 2001). Interest-
ingly, HeLa cells are derived from an uterine tumour, which
suggests that ST-5 may be hormonally regulated. However, little is
known about the regulation and the expression of this tumour
suppressor. Future interests will allow a better understanding of
the role of ST-5 in the gynaecological female tract cancers such as
ovarian and uterine cancers.
Among the genes differentially expressed in malignant EOC is
Msln. Mesothelin mRNA has previously been described as
overexpressed in ovarian and mesothelioma cancer tissues, and
the gene product is referred to a marker of these two cancers
(Ordonez, 2003; Drapkin et al, 2004; McIntosh et al, 2004).
However, these studies analysed the Msln protein expression using
a small number of samples, and usually limited their analysis to
serous ovarian cancer samples. We extended these observations on
a larger set of samples also containing endometrioid and clear cell
tissues with different tumour grades. In contrast to the general
statement that Msln is a specific ovarian cancer marker, here we
observed that normal epithelial cells can at times express Msln and
a weak or absent expression is observed in both low-grade
endometrioid and clear cell tumours. Our extended analysis would
thus emphasise that no unique protein marker may be appropriate
to classify such a heterogeneous disease, and reinforces the notion
that a combination of protein markers is possibly necessary to
allow the correct distinction of normal and cancerous ovarian
epithelial cells. Our results support this idea but do not rule out the
idea that Msln may be an appropriate ovarian cancer marker in
association with other markers, such as BMP-2, that complement
staining in low-grade endometrioid and clear cell tumours.
In conclusion, our results indicate that a molecular classification
system, based on the statistical analysis of gene expression
profiling, is a useful approach for tumour subgrouping and the
discovery of new molecular markers. These observations articulate
a new area of research in the understanding of ovarian cancer as
well as illuminating new therapeutic strategies. Combination of
oligo-microarray, RT–PCR and tissue array linked to clinical and
pathology data will facilitate rapid characterisation of candidate
markers.
ACKNOWLEDGEMENTS
We are grateful to the staff and patients at the Department of Onco-
Gynecology at the Ho ˆpital Notre-Dame de Montre ´al for providing
the samples. We thank Lise Portelance, Manon de Ladurantaye,
Louise Champoux, Ste ´phanie Girard, and Dr Herve Koumakpahi for
their assistance. We are grateful to Dr Mario Fillion for RNA
amplification and Dr Ali Filali, for bioinformation. We also thank Dr
Nadia Benhachenhou and the ‘oncotree group’ for useful discus-
sions. This work was supported by a grant from the Canadian
Institutes of Health Research (CIHR) to A-MM-M, PNT, DMP and
TJH. Tumor banking was supported by the Banque de tissus et de
donne ´es of the Re ´seau de recherche sur le cancer of the Fonds de la
recherche en sante ´ du Que ´bec (FRSQ). VO was supported by
studentships from the CIHR and Canderel fund of the Institut du
cancer de Montre ´al. FR was supported by a Wyeth-CIHR-sponsored
fellowship and PNT is a recipient of a Frazer, Monat and Mc
Pherson Scholarship and the Stewart Fellowship in Research/Clinical
Hematology and Oncology. TJH is recipient of an Investigator
Award from CIHR and a Clinician-scientist Award in Translational
Research from the Burroughs Wellcome Fund. DMP is a recipient of
a Chercheur-Clinicien Senior and A-MM-M is a recipient of a
Chercheur National, all fellowships provided by the FRSQ.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, Ledermann J,
Boshoff C (2004) Predicting biomarkers for ovarian cancer using gene-
expression microarrays. Br J Cancer 90: 686–692
Amid C, Bahr A, Mujica A, Sampson N, Bikar SE, Winterpacht A, Zabel B,
Hankeln T, Schmidt ER (2001) Comparative genomic sequencing reveals
a strikingly similar architecture of a conserved syntenic region on human
chromosome 11p15.3 (including gene ST5) and mouse chromosome 7.
Cytogenet Cell Genet 93: 284–290
Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L,
Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S,
Taylor JM, Iannettoni MD, Orringer MB, Hanash S (2002) Gene-
expression profiles predict survival of patients with lung adenocarcino-
ma. Nat Med 8: 816–824
Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003)
Improved survival in women with BRCA-associated ovarian carcinoma.
Cancer 97: 2187–2195
Chang XH, Cheng YX, Zhang XY, Cui H, Feng J (2003) [Monitoring novel
ovarian carcinoma associated genes using cDNA expression microarray].
Zhonghua Fu Chan Ke Za Zhi 38: 322–324
Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih
JH, Barrett JC, Birrer MJ (2004) Whole genome expression profiling of
advance stage papillary serous ovarian cancer reveals activated pathways.
Oncogene 23: 8065–8077
Drapkin R, Crum CP, Hecht JL (2004) Expression of candidate tumor
markers in ovarian carcinoma and benign ovary: evidence for a link
between epithelial phenotype and neoplasia. Hum Pathol 35: 1014–1021
Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-
Dutoit S, Wolf H, Orntoft TF (2003) Identifying distinct classes of
bladder carcinoma using microarrays. Nat Genet 33: 90–96
Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of
cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Lancet 343: 692–695
Gilks CB, Vanderhyden BC, Zhu S, van de Rijn M, Longacre TA (2005) Distinc-
tion between serous tumors of low malignant potential and serous carcinomas
b a s e do ng l o b a lm R N Ae x p r e s s i o np r o f i l i n g .Gynecol Oncol 96: 684–694
Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP,
Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES
(1999) Molecular classification of cancer: class discovery and class
prediction by gene expression monitoring. Science 286: 531–537
Gordon GJ, Richards WG, Sugarbaker DJ, Jaklitsch MT, Bueno R (2003) A
prognostic test for adenocarcinoma of the lung from gene expression
profiling data. Cancer Epidemiol Biomarkers Prev 12: 905–910
Gene expression of epithelial ovarian cancer
C Le Page et al
444
British Journal of Cancer (2006) 94(3), 436–445 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sHibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema
TR, Jr, Thiele JJ, Grindle SM, Bliss RL, Skubitz AP (2004) Differential
gene expression in ovarian carcinoma: identification of potential
biomarkers. Am J Pathol 165: 397–414
Kruk PA, Maines-Bandiera SL, Auersperg N (1990) A simplified method to
culture human ovarian surface epithelium. Lab Invest 63: 132–136
Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR,
Nevins JR, Berchuck A (2004) Gene expression patterns that characterize
advanced stage serous ovarian cancers. J Soc Gynecol Investig 11: 51–59
Le Page C, Provencher D, Maugard CM, Ouellet V, Mes-Masson AM (2004)
Signature of a silent killer: expression profiling in epithelial ovarian
cancer. Expert Rev Mol Diagn 4: 157–167
Lee BC, Cha K, Avraham S, Avraham HK (2004) Microarray analysis of
differentially expressed genes associated with human ovarian cancer. Int
J Oncol 24: 847–851
Lichy JH, Modi WS, Seuanez HN, Howley PM (1992) Identification of a
human chromosome 11 gene which is differentially regulated in
tumorigenic and nontumorigenic somatic cell hybrids of HeLa cells.
Cell Growth Differ 3: 541–548
Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, Mes-Masson AM
(1994) Primary cultures of normal and tumoral human ovarian
epithelium: a powerful tool for basic molecular studies. Exp Cell Res
215: 303–309
Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA,
Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L,
Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills
GB, Bast Jr RC (2004) Selection of potential markers for epithelial
ovarian cancer with gene expression arrays and recursive descent
partition analysis. Clin Cancer Res 10: 3291–3300
Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK,
Clarke-Pearson DL, Iglehart JD, Bast Jr RC, Berchuck A (1991)
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer
Res 51: 2979–2984
McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE,
Hellstrom I (2004) Combining CA 125 and SMR serum markers
for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol
95: 9–15
Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM,
Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli
J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM
(2005) Molecular and prognostic distinction between serous ovarian
carcinomas of varying grade and malignant potential. Oncogene 24:
1053–1065
Meltzer PS, Jankowski SA, Dal Cin P, Sandberg AA, Paz IB, Coccia MA
(1991) Identification and cloning of a novel amplified DNA sequence
in human malignant fibrous histiocytoma derived from a region of
chromosome 12 frequently rearranged in soft tissue tumors. Cell Growth
Differ 2: 495–501
Neibergs HL, Hein DW, Spratt JS (2002) Genetic profiling of colon cancer.
J Surg Oncol 80: 204–213
Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada
M, Yokota J (1991) Frequent allelic losses and mutations of the p53 gene
in human ovarian cancer. Cancer Res 51: 5171–5176
Ordonez NG (2003) Application of mesothelin immunostaining in tumor
diagnosis. Am J Surg Pathol 27: 1418–1428
Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Lussier C,
Novak J, Ge B, Hudson TJ, Tonin PN, Mes-Masson AM (2005)
Discrimination between serous low malignant potential and invasive
epithelial ovarian tumors using molecular profiling. Oncogene 24:
4672–4687
Palazzo JP, Monzon F, Burke M, Hyslop T, Dunton C, Barusevicius A,
Capuzzi D, Kovatich AJ (2000) Overexpression of p21WAF1/CIP1 and
MDM2 characterizes serous borderline ovarian tumors. Hum Pathol 31:
698–704
Pfaffl MW (2001) A new mathematical model for relative quantification in
real-time RT–PCR. Nucleic Acids Res 29: e45
Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M,
Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M,
Lander ES, Golub TR (2001) Multiclass cancer diagnosis using tumor
gene expression signatures. Proc Natl Acad Sci USA 98: 15149–15154
Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey
SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D,
Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000)
Systematic variation in gene expression patterns in human cancer cell
lines. Nat Genet 24: 227–235
Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S,
Gokden M, Dunn D, Roman JJ, O’Brien TJ, Tian E, Cannon MJ,
Shaughnessy Jr J, Pecorelli S (2004) Gene expression profiles in primary
ovarian serous papillary tumors and normal ovarian epithelium:
identification of candidate molecular markers for ovarian cancer
diagnosis and therapy. Int J Cancer 112: 14–25
Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M,
Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP,
Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero MJ, Kristensen
GB, Borresen-Dale AL, Hastie T, Tibshirani R, van de Rijn M, Teng NN,
Longacre TA, Botstein D, Brown PO, Sikic BI (2003) Gene expression
patterns in ovarian carcinomas. Mol Biol Cell 14: 4376–4386
Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM,
Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ,
Fearon ER, Hanash SM, Cho KR (2002) Gene expression in ovarian
cancer reflects both morphology and biological behavior, distinguishing
clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62:
4722–4729
Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC,
Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA,
Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster
JC, Golub TR (2002) Diffuse large B-cell lymphoma outcome prediction
by gene-expression profiling and supervised machine learning. Nat Med
8: 68–74
Simon R (2003) Using DNA microarrays for diagnostic and prognostic
prediction. Expert Rev Mol Diagn 3: 587–595
Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E,
Lander ES, Golub TR (1999) Interpreting patterns of gene expression
with self-organizing maps: methods and application to hematopoietic
differentiation. Proc Natl Acad Sci USA 96: 2907–2912
Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays
applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:
5116–5121
van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse
HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven
RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene
expression profiling predicts clinical outcome of breast cancer. Nature
415: 530–536
Warrenfeltz S, Pavlik S, Datta S, Kraemer ET, Benigno B, McDonald JF
(2004) Gene expression profiling of epithelial ovarian tumours correlated
with malignant potential. Mol Cancer 3: 27
Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ,
Lockhart DJ, Burger RA, Hampton GM (2001) Analysis of gene
expression profiles in normal and neoplastic ovarian tissue samples
identifies candidate molecular markers of epithelial ovarian cancer. Proc
Natl Acad Sci USA 98: 1176–1181
Zhang X, Feng J, Cheng Y, Yao Y, Ye X, Fu T, Cheng H (2005)
Characterization of differentially expressed genes in ovarian cancer by
cDNA microarrays. Int J Gynecol Cancer 15: 50–57
Gene expression of epithelial ovarian cancer
C Le Page et al
445
British Journal of Cancer (2006) 94(3), 436–445 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s